Nachrichten zur ASTELLAS PHARMA INC. Aktie

Astellas Pharma Inc. (ALPMF) Q2 2024 Earnings Call Transcript

…

Global Prostate Health Market Size To Worth USD 78.03 Billion By 2033 | CAGR Of 9.12%

The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023 and the Worldwide Prostate Health Market…

Astellas Pharmas Okamura on Business Outlook

Naoki Okamura, CEO of Astellas Pharma, discusses his business strategy for the company and the outlook for Japans economic growth…

Antiandrogens Market Insights and Projections to 2030: An $8.7 Billion Landscape Dominated by Pfizer, Astellas Pharma, Roche, AstraZeneca, and Abbott Labs

Dublin, May 21, 2024 (GLOBE NEWSWIRE) -- The "Antiandrogens Market Report: Trends, Forecast and Competitive Analysis to 2030"…

Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma

The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake,…

Earnings call: Astellas Pharma exceeds revenue forecast, faces profit dip By Investing.com

Earnings call: Astellas Pharma exceeds revenue forecast, faces profit dip…

Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript

…

Vasomotor Symptoms Market is Likely to Increase at a Steady Growth Rate by 2034, Estimated DelveInsight | Key Companies - Estetra, Bayer, Hansoh BioMedical R&D Company, Mitsubishi Tanabe Pharma, Astellas Pharma Inc

The vasomotor symptoms market is expected to experience substantial growth in the upcoming years, driven by the introduction of new…

Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript

…

Astellas Pharma Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Global Transplantation Market Size To Exceed USD 21.2 Billion By 2032 | CAGR of 9.5%

The Global Transplantation Market Size was valued at USD 8.5 Billion in 2022 and the Worldwide Transplantation Market Size is…

Dividend Investors Should Look Abroad. 3 Stocks From Europe and Japan.

International equities yield more and cost less on average than U.S. stocks. Legrand, RELX, and Astellas Pharma are among the…

Seagens (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag

Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under…

[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

…

Astellas Pharma Inc. 2023 Q2 - Results - Earnings Call Presentation

…

Astellas Pharma-Aktie heute gut behauptet: Aktienwert steigt (12,325 €)

Im Plus liegt gegenwärtig der Anteilsschein von Astellas Pharma . Der jüngste Kurs betrug 12,33 Euro. Am Aktienmarkt hat sich…

Immer noch ein Tabu? Beschwerden rund um die Wechseljahre müssen in den Fokus

München (ots) - - Astellas Pharma initiiert repräsentative Umfrage mit über 1.000 Frauen in Deutschland zwischen 40 und 65 Jahren…

Prostate Health Market Size to Hit $ 82.64 Bn by 2032 | Rapid Advancements & Innovation in Prostate Health Treatments

[230+ Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…

Mucous Membrane Decontamination Market revenue to surpass USD 15 Billion by 2035, says Research Nester

Major mucous membrane decontamination market players include Astellas Pharma Inc., Bausch Health Companies Inc., Genentech, Inc., Lipidor AB., Pfizer Inc.,…

: Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts

Apellis Pharmaceuticals Inc. shares APLS jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc.…

Astellas Pharma to build a new $330M facility in Ireland

…

Sandoz Concludes Acquisition Of Antifungal Agent Mycamine From Astellas

BASEL (dpa-AFX) - Sandoz a unit of biopharmaceutical major Novartis AG (NVS) said on Monday that it has completed acquiring…

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

Basel, August 28, 2023 – Sandoz, a global leader in generic and biosimilar medicines, has successfully completed the acquisition of…

Pfizer, Astellas win FDA priority review for Xtandi label expansion

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Apellis falls as Astellas wins FDA nod for rival product

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Poseida jumps on $50M investment from Astellas

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Poseida Therapeutics Shares Leap on Astellas Investments >PSTX

Poseida Therapeutics Shares Leap on Astellas Investments >PSTX...…

Poseida Therapeutics in $50 Million Investment Deal With Astellas >PSTX

Poseida Therapeutics in $50 Million Investment Deal With Astellas >PSTX...…

Astellas Pharma Secures US FDA Approval for Izervay

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Solu Therapeutics raises funds to develop CyTaC platform and drug candidates

Co-led by Santé Ventures and Longwood, the financing round has seen participation from Alexandria Venture Investments, Astellas Venture Management, and…

Japanese Detained in China Gets 1st In-Person Consular Visit

Beijing, July 21 (Jiji Press)--The Japanese Embassy in Beijing made its first consular visit in person to a Japanese man…

Japan Embassy granted in-person access to detained national in China

The Japanese Embassy in Beijing has been granted in-person consular access to an employee of pharmaceutical firm Astellas Pharma Inc.,…

Astellas Pharma completes acquisition of Iveric Bio

In April this year, Astellas Pharmas subsidiary agreed to buy 100% of the outstanding shares of Iveric Bio for $40 per share in…

Astellas Completes Acquisition of Iveric Bio

TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura,…

4D Molecular spikes on licensing deal with Astellas

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Iveric Bio ticks higher as it sees sale to Astellas closing July 11

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Iveric Bio falls amid concern about Astellas deal

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas :Phase 3 Trial Of Fezolinetant Shows Positive Results For Treatment Of VMS Due To Menopause

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive results from the Phase 3b DAYLIGHT clinical trial for fezolinetant,…

Iveric Bio gains after HSR waiting period for Astellas deal expires

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas, Cullgen Team Up To Discover Innovative Targeted Protein Degraders

BEIJING (dpa-AFX) - Biopharmaceutical companies Astellas Pharma Inc. (ALPMY) and Cullgen Inc, announced on Thursday a research collaboration and exclusive…

Astellas Submits NDA For Zolbetuximab In Japan For Advanced Gastric, Gastroesophageal Cancers

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced Friday the submission of a New Drug Application or NDA to Japans…

Astellas, Kate Therapeutics Ink License Agreement For Gene Therapy Candidate KT430

WASHINGTON (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Kate Therapeutics, announced on Thursday that they have entered an exclusive license…

BRIEF-Kate Therapeutics Grants Astellas Pharma Exclusive License To Manufacture And Commercialize KT430 To Treat X-Linked Myotubular Myopathy

...June 8 (Reuters) - * KATE THERAPEUTICS - DEBUTS $51 MILLION SERIES......…

dpa-AFX ProFeed